Sibyl Nichole Swift - 17 Feb 2023 Form 4 Insider Report for cbdMD, Inc. (YCBD)

Role
Director
Signature
/s/ Sybil Swift
Issuer symbol
YCBD
Transactions as of
17 Feb 2023
Net transactions value
$0
Form type
4
Filing time
22 Feb 2023, 15:29:01 UTC
Previous filing
11 Aug 2022
Next filing
03 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YCBD Common Stock Award $0 +5,000 +49% $0.000000 15,250 17 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YCBD Stock Options (Right to Buy) Award +30,000 30,000 17 Feb 2023 Common Stock 30,000 $0.2800 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted stock units are fully vested. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for her services on the Issuer's Board of Directors for the Board term beginning February 16, 2023.
F2 The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning February 16, 2023. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The stock options are fully vested.
F3 Not applicable.